Bristol Myers to acquire Forbius for its TGF-beta inhibitor pipeline
Forbius develops a portfolio of selective potent inhibitors of TGF-beta 1 & 3, which mediate immunosuppression and fibrosis
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Aug 20
Forbius develops a portfolio of selective potent inhibitors of TGF-beta 1 & 3, which mediate immunosuppression and fibrosis
25 Aug 20
The sale of consumer health care business will further strengthen Takeda’s focus on five key business areas, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Aug 20
The acquisition will enable J&J’s pharmaceutical business Janssen to expand its operations in immune-mediated diseases and autoantibody-driven diseases
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
18 Aug 20
Principia Biopharma is a late-stage biopharmaceutical company that develops transformative therapies for immune-mediated diseases
11 Aug 20
Ligand will pay $2 per share, valuing a total of $78m as a Contingent Value Right (CVR) in…
22 Jul 20
Along with the 49.9% stake, Gilead Sciences also received an exclusive option to acquire the remaining stake in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Jul 20
GSK will pay $131m upfront in cash and make one-time reimbursable payment of $32.8m to reserve the manufacturing…
17 Jul 20
The revised bid has raised the initial offer price of €39.00 per share to a new price of…
29 Jun 20
Piramal Pharma includes Piramal Pharma Solutions, an end-to-end contract development and manufacturing (CDMO) business, Piramal Critical Care, a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Jun 20
Pionyr Immunotherapeutics is a privately held pharmaceutical company engaged in developing a research approach, dubbed Myeloid Tuning
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates